This competitive landscape analysis was generated using AI-powered research workflows in Eureka LS, which integrates patent data, literature, and molecular insights into a structured report in minutes.
Executive Summary
The colorectal cancer (CRC) therapeutic landscape is undergoing a structural shift from broad chemotherapy backbones toward molecularly stratified precision therapies. The arena is highly active: 331 approved drugs (across all lines/indications), 142 in Phase 3, and 317 in Phase 2 are indexed against CRC. Three dominant technology routes define the competitive frontier — VEGF/angiogenesis inhibition (Roche/Genentech-led), KRAS G12C inhibition (Amgen, BMS/Mirati, and a cluster of Chinese biotechs), and PD-1/checkpoint immunotherapy (Merck, BMS, Chinese PD-1 players). A fourth wave of bispecific antibodies and ADCs targeting EGFR, HER2, and TROP2 is now entering the arena with positive Phase 3 readouts. Chinese players have moved decisively from followership to origination, particularly in KRAS inhibitors and PD-1/VEGF bispecifics, creating a genuine domestic-vs-overseas competitive tension.
Traditionally, compiling this level of analysis would require weeks of manual research across platforms like Google Patents and PubMed. With Eureka LS, the same process can be automated—from extracting molecules to mapping competitive pipelines—into a structured output like the report below.
Arena Overview
| Player | Region | Tier | Primary Route | Key Asset(s) |
|---|---|---|---|---|
| Roche/Genentech | Global | T1 | VEGF-A inhibition + KRAS G12C | Bevacizumab (approved 2004), Divarasib (Ph3) |
| Merck & Co. (MSD) | US/Global | T1 | PD-1 / MSI-H CRC | Pembrolizumab (approved, MSI-H) |
| Bristol Myers Squibb | US/Global | T1 | PD-1 + KRAS G12C | Nivolumab (approved), Adagrasib (approved 2022) |
| J&J (Janssen) | US/Global | T1 | EGFR/MET bispecific | Amivantamab (OrigAMI-2/3 Ph3 positive) |
| Amgen | US | T2 | KRAS G12C pioneer | Sotorasib (approved 2021, CRC combo) |
| Pfizer | US/Global | T2 | BRAF V600E | Encorafenib (BEBC regimen, Ph3 positive) |
| Bayer | Global | T2 | Multi-kinase | Regorafenib (approved 2012, 3L+) |
| Akeso | China | T2 | PD-1/VEGF bispecific | Ivonescimab (approved 2024, HARMONi-GI3 Ph3) |
| Agenus | US | T2 | Fc-enhanced CTLA4+PD-1 | Botensilimab + Balstilimab (BATTMAN Ph3) |
| Genfleet | China | T3 | KRAS G12C | Fulzerasib (approved 2024-08) |
| Jacobio | China | T3 | KRAS G12C | Glecirasib (approved 2025-05) |
| InventisBio | China | T3 | KRAS G12C | Garsorasib (approved 2024-11) |
| Astellas | Japan | T3 | KRAS G12D PROTAC | Setidegrasib (Ph3) |
| Lepu Biopharma | China | T3 | EGFR ADC | Becotatug vedotin (approved 2025-10) |
Route Differentiation Analysis
Route Differentiation Matrix
| Player | VEGF/Angiogenesis | KRAS G12C | PD-1/Checkpoint | EGFR/HER2 | BRAF/RAS Pathway | Novel Modalities |
|---|---|---|---|---|---|---|
| Roche/Genentech | Strong (Bevacizumab, backbone SoC) | Strong (Divarasib Ph3) | Moderate (Atezolizumab) | Moderate (Cetuximab rights) | — | — |
| MSD | — | — | Strong (Pembrolizumab, MSI-H approved) | — | — | — |
| BMS | — | Strong (Adagrasib approved) | Strong (Nivolumab, MSI-H) | — | — | — |
| J&J | — | — | — | Strong (Amivantamab EGFR/MET bispecific, Ph3 positive) | — | Bispecific |
| Amgen | — | Strong (Sotorasib, pioneer) | — | — | — | — |
| Pfizer | — | — | — | Moderate (Cetuximab rights) | Strong (Encorafenib, BRAF V600E) | — |
| Bayer | Moderate (Regorafenib multi-kinase) | — | — | — | Moderate (Regorafenib) | — |
| Akeso | Moderate | — | Strong (Ivonescimab PD-1/VEGF bispecific) | — | — | Bispecific |
| Agenus | — | — | Emerging (Botensilimab+Balstilimab, MSS CRC) | — | — | Fc-enhanced |
| Genfleet | — | Moderate (Fulzerasib approved) | — | — | — | — |
| Jacobio | — | Moderate (Glecirasib approved) | — | — | — | — |
| InventisBio | — | Moderate (Garsorasib approved) | — | — | — | — |
| Astellas | — | — | — | — | Emerging (Setidegrasib KRAS G12D PROTAC) | PROTAC |
| Lepu Biopharma | — | — | — | Emerging (Becotatug vedotin EGFR ADC) | — | ADC |
Route Concentration Summary
Generate Competitive Landscape Reports Like This — in Minutes
Powered by Eureka LS AI
- ✔ Analyze patents, literature, and pipelines together
- ✔ Extract molecule & SAR data automatically
- ✔ Compare competitors and identify key assets
- ✔ Get structured reports instantly
Top Player Deep Dives
1. Roche / Genentech — VEGF Anchor + KRAS Challenger
Primary route: VEGF-A inhibition (Bevacizumab) as the dominant backbone of first-line mCRC chemotherapy; now investing in KRAS G12C with Divarasib.
- Bevacizumab (approved Feb 2004) remains the most widely used anti-angiogenic in CRC globally, indicated across multiple lines in combination with FOLFOX/FOLFIRI/XELOX. The Roche Korea / HK inno.N Avastin promotion deal (Jan 2025) signals continued commercial investment.
- Divarasib (KRAS G12C inhibitor, Phase 3) is Roche/Genentech’s bid to enter the KRAS G12C space, directly competing with Amgen’s Sotorasib and BMS’s Adagrasib. It is being studied in combination with Cetuximab for CRC.
- Route bet: Roche is pursuing a combination strategy — KRAS G12C inhibitor + EGFR antibody — to overcome the EGFR feedback activation that limits single-agent KRAS G12C efficacy in CRC.
- Trajectory: Strong. Bevacizumab biosimilar competition is a headwind, but Divarasib combination data could re-establish leadership in the KRAS-mutant CRC segment.
2. Merck & Co. (MSD) — PD-1 / MSI-H Franchise
Primary route: PD-1 inhibition exclusively in biomarker-selected (MSI-H/dMMR) CRC.
- Pembrolizumab (approved Sep 2014; CRC-specific approval for MSI-H/dMMR) is the standard of care for first-line MSI-H/dMMR metastatic CRC (KEYNOTE-177 data). The SC formulation Pembrolizumab/Hyaluronidase received approval Sep 2025.
- Route limitation: MSI-H/dMMR accounts for only ~5% of metastatic CRC — limiting the addressable population. The remaining ~95% of MSS CRC is largely refractory to PD-1 monotherapy.
- Strategic bet: MSD is exploring combinations (chemotherapy, anti-VEGF, novel IO) to extend into MSS CRC, but no Phase 3 positive read has been reported as of current data.
- Trajectory: Dominant in MSI-H niche; limited upside without MSS CRC breakthrough.
3. Bristol Myers Squibb — Dual Franchise (PD-1 + KRAS G12C)
Primary route: PD-1 (Nivolumab) for MSI-H CRC; KRAS G12C (Adagrasib, acquired via Mirati) for KRAS-mutant CRC.
- Nivolumab (approved Jul 2014; CRC-specific: MSI-H rectal cancer, CheckMate-142) provides BMS a presence in the IO-sensitive CRC population.
- Adagrasib (approved Dec 2022 for KRAS G12C NSCLC; CRC combination data with cetuximab in KRYSTAL-10) — BMS acquired Mirati Therapeutics to secure this asset. Adagrasib + cetuximab combination has shown ~46% ORR in KRAS G12C CRC (vs ~7% for adagrasib monotherapy), validating the combination approach.
- BATTMAN trial: Botensilimab + Balstilimab (Agenus, in partnership with BMS distribution) vs best supportive care in chemo-refractory MSS CRC (Ph3 recruiting).
- Trajectory: Well-positioned with two differentiated routes; Adagrasib combination data in CRC is a key near-term catalyst.
4. Johnson & Johnson (Janssen) — EGFR/MET Bispecific Disruptor
Primary route: EGFR/MET bispecific antibody (Amivantamab) as a potential replacement for cetuximab/panitumumab in RAS/BRAF wild-type mCRC.
- Amivantamab (EGFR/MET bispecific): Two pivotal Phase 3 trials in CRC with positive results:
- OrigAMI-2: Amivantamab vs cetuximab + FOLFOX or FOLFIRI as 1L treatment in left-sided RAS/BRAF WT mCRC — Positive
- OrigAMI-3: Amivantamab + FOLFIRI vs cetuximab or bevacizumab + FOLFIRI in recurrent/metastatic RAS/BRAF WT CRC — Positive
- Significance: These positive readouts position J&J as a potential new Tier 1 player in RAS/BRAF WT CRC, challenging the established cetuximab/panitumumab duopoly. Regulatory submissions are anticipated.
- Trajectory: Ascending rapidly. OrigAMI positive data is the single most significant competitive move in CRC in 2025.
5. Amgen — KRAS G12C Pioneer
Primary route: KRAS G12C inhibition (first-in-class).
- Sotorasib (approved May 2021) was the first approved KRAS G12C inhibitor. In CRC, the CodeBreaK 300 trial (sotorasib 960mg + panitumumab) showed improved PFS vs standard of care in chemorefractory KRAS G12C mCRC, leading to FDA approval in the CRC combination setting.
- Competitive pressure: Amgen faces a crowded field — Adagrasib (BMS/Mirati) is approved and showing superior combination data; Chinese KRAS inhibitors (Fulzerasib, Glecirasib, Garsorasib) are approved in China; Divarasib (Roche) is in Ph3. Sotorasib’s CRC monotherapy ORR (~9%) is modest.
- Route bet: Combination with EGFR antibody (panitumumab) to overcome feedback resistance is the validated path.
- Trajectory: Stable but under pressure from later entrants with better combination data.
6. Pfizer — BRAF V600E Niche Leader
Primary route: BRAF V600E inhibition (Encorafenib) in BRAF V600E-mutant CRC (~8-10% of mCRC).
- Encorafenib (BRAFTOVI, BRAF inhibitor): The BEACON CRC trial established encorafenib + cetuximab (BEBC regimen) as standard of care for BRAF V600E-mutant mCRC. Phase 3 data showed the BRAFTOVI regimen with additional chemotherapy backbone increased response rates.
- Market position: Dominant in the BRAF V600E-mutant CRC niche; limited by biomarker prevalence (~8-10%).
- Trajectory: Stable niche position; exploring triplet combinations (encorafenib + cetuximab + chemotherapy) to further improve outcomes.
7. Akeso — Chinese PD-1/VEGF Bispecific Leader
Primary route: PD-1/VEGF bispecific antibody (Ivonescimab) — simultaneous PD-1 and VEGF blockade in a single molecule.
- Ivonescimab (approved May 2024 in China) is being evaluated in CRC in the HARMONi-GI3 Phase 3 trial (Ivonescimab or Bevacizumab + FOLFOX in mCRC, recruiting).
- Strategic logic: If Ivonescimab can replace both bevacizumab and a PD-1 antibody in one agent, it simplifies the treatment regimen and could challenge the Roche/MSD combination approach.
- Virogin collaboration: Akeso’s AK112 (Ivonescimab) is being combined with Virogin’s VG201 for CRC liver metastasis.
- Trajectory: High-potential challenger; HARMONi-GI3 results will be a defining catalyst for the PD-1/VEGF bispecific route in CRC.
8. Agenus — MSS CRC Immunotherapy Challenger
Primary route: Fc-enhanced CTLA-4 + PD-1 combination (Botensilimab + Balstilimab) targeting the immunologically “cold” MSS CRC population.
- Botensilimab (Fc-enhanced anti-CTLA-4) + Balstilimab (anti-PD-1): Phase 3 BATTMAN trial vs best supportive care in chemo-refractory, unresectable MSS colorectal adenocarcinoma is actively recruiting.
- Significance: MSS CRC represents ~95% of metastatic CRC and is largely refractory to current IO. Botensilimab’s Fc-enhancement is designed to improve T-cell priming in cold tumors. Phase 1/2 data showed ~14% ORR in chemo-refractory MSS CRC — modest but unprecedented for this population.
- Tanner Pharma partnership for global access to Botensilimab/Balstilimab (Dec 2024).
- Trajectory: High-risk, high-reward. BATTMAN Ph3 readout is one of the most watched events in CRC IO.
9. Chinese KRAS G12C Cluster (Genfleet, Jacobio, InventisBio)
Three Chinese biotechs have each achieved NMPA approval for KRAS G12C inhibitors in rapid succession:
| Company | Drug | Approval Date | Notes |
|---|---|---|---|
| Genfleet + Innovent | Fulzerasib | Aug 2024 | First Chinese KRAS G12C inhibitor approved |
| InventisBio + CTTIC | Garsorasib | Nov 2024 | Garsorasib |
| Jacobio | Glecirasib | May 2025 | Broadest disease coverage (13 indications) |
- All three target KRAS G12C (same target as Sotorasib/Adagrasib) and compete primarily in the China market.
- The Jacobio KRAS G12C + SHP2 inhibitor deal with Allist (valued up to ¥850M) signals active combination strategy development.
- Sosimerasib (Shanghai Jiyu, approved Feb 2026) adds a fourth Chinese KRAS G12C inhibitor to the domestic market.
Domestic vs Overseas Comparison
| Dimension | Global (US/EU) Players | Chinese Players |
|---|---|---|
| Standard of care anchor | FOLFOX/FOLFIRI + Bevacizumab or Cetuximab (RAS WT) | Same backbone; domestic biosimilars widely used |
| KRAS G12C | Sotorasib (Amgen, pioneer), Adagrasib (BMS/Mirati), Divarasib (Roche, Ph3) | 4 approved: Fulzerasib, Garsorasib, Glecirasib, Sosimerasib — all NMPA-approved 2024–2026 |
| Checkpoint IO | Pembrolizumab, Nivolumab (MSI-H approved); Botensilimab (MSS, Ph3) | Finotonlimab (approved Feb 2025), Enlonstobart (approved Jun 2024), multiple domestic PD-1s |
| Bispecifics | Amivantamab EGFR/MET (J&J, Ph3 positive) | Ivonescimab PD-1/VEGF (Akeso, approved + HARMONi-GI3 Ph3) |
| ADCs | Trastuzumab Rezetecan (DS-8201 biosimilar, approved May 2025); Patritumab Deruxtecan (Ph3) | Becotatug vedotin EGFR ADC (Lepu, approved Oct 2025) |
| BRAF V600E | Encorafenib (Pfizer, approved, BEBC regimen) | Limited domestic competition |
| KRAS G12D / next-gen KRAS | Setidegrasib (Astellas PROTAC, Ph3); Divarasib (Roche) | IBI-363 (Innovent PD-1/IL-2 fusion, Ph3) |
| Innovation origin | Predominantly originator | Increasingly originator (Akeso, Jacobio, Genfleet); some licensed-in |
| Speed to approval | FDA/EMA timelines (12–18 months post-NDA) | NMPA accelerating; KRAS inhibitors approved within 1–2 years of US |
| Combination strategy | KRAS G12C + EGFR mAb (validated); PD-1 + chemo (MSI-H) | KRAS G12C + SHP2; PD-1/VEGF bispecific + chemo |
Key structural difference: Global players (Roche, MSD, BMS, J&J) maintain dominance in the RAS/BRAF WT and MSI-H segments. Chinese players are primarily competing in the KRAS G12C inhibitor space (domestic market) and are beginning to generate globally competitive bispecific data (Akeso’s Ivonescimab). The ADC route is emerging on both sides simultaneously, with both domestic (Lepu/Kelun) and global (Daiichi/AstraZeneca) players entering CRC.
If you want to generate similar competitive landscape reports for other targets, drugs, or companies, AI tools like Eureka LS can significantly reduce the time and effort required, while improving consistency and depth of analysis.
Risks, Emerging Spaces, and Observations
Key competitive risks:
- KRAS G12C crowding: With 4+ approved agents in China and 3 globally, pricing pressure and differentiation challenges are acute. The clinical bar is shifting from monotherapy to combination (KRAS + EGFR or KRAS + SHP2).
- MSS CRC remains largely unmet: ~95% of mCRC is MSS and IO-refractory. Botensilimab (Agenus) is the leading challenger, but Phase 3 data is pending. If BATTMAN fails, the MSS IO space remains open.
- Bispecific antibody inflection: J&J’s OrigAMI positive data is the most significant near-term disruptor — if approved, Amivantamab could displace cetuximab/panitumumab as the EGFR-targeting standard in RAS/BRAF WT mCRC.
- ADC wave: Trastuzumab Rezetecan, Becotatug vedotin, and Patritumab Deruxtecan (HER3-DXd) are entering CRC in HER2-amplified and EGFR-expressing subpopulations. This route is early but moving fast.
- Next-generation KRAS: KRAS G12D (Setidegrasib PROTAC by Astellas, Ph3) and pan-KRAS approaches represent the next wave after G12C saturation.
Emerging observation — KRAS G12D PROTAC: Astellas’ Setidegrasib (KRAS G12D degrader, Phase 3) targets KRAS G12D, which is the most prevalent KRAS mutation in CRC (~35–40% of KRAS-mutant CRC). If successful, this opens a far larger addressable population than KRAS G12C (~3–4% of mCRC). This is a high-priority watchlist item.
Evidence gaps: Full clinical outcome data (OS, PFS) for most recent approvals (Glecirasib, Becotatug vedotin, Sosimerasib in CRC-specific settings) were not available in current-turn retrieval and require dedicated clinical outcome analysis for quantitative benchmarking.
Turn Complex Data into Decision-Ready Insights
Use Eureka LS to generate competitive intelligence reports across any target, drug, or company.
- ✔ Domain-specific research Q&A
- ✔ Patent & literature analysis (2 files per upload)
- ✔ Lead compound analysis with SAR extraction (5 runs)
- ✔ 2 AI-powered Pulse briefs for early signals
